Company Overview
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +41.67% |
| 6 Months: | +0.00% |
| 3 Months: | -22.73% |
| 1 Month: | -17.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)27.87 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 35.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OKUR OnKure Therapeutics, Inc. PHARMA | 3.40 | -1.12 | $137.34M | 0.00% | -112.02% | -46.91% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.00M | 16.32M | 15.50M | 14.12M | 15.62M | - |
| Operating Income | -4.50M | -3.70M | -5.10M | -7.21M | -9.23M | -12.75M | -13.02M | -12.43M | -13.84M | -16.12M | -21.04M | -20.89M | -9.83M | -14.34M | -11.51M | - | -17.00M | -16.32M | -15.50M | -14.12M | -15.62M | -16.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.79M | -15.18M | -14.49M | -13.29M | -15.41M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 2.00K | 6.00K | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.93M | -15.39M | -14.70M | -13.50M | -15.16M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.43M | -3.69M | -5.09M | -7.21M | -9.22M | -12.73M | -13.04M | -12.31M | -13.01M | -15.11M | -19.53M | -19.20M | -9.54M | -14.14M | -11.56M | -17.44M | -15.93M | -15.39M | -14.70M | -13.50M | -15.16M | -15.35M |
| Diluted EPS | - | - | - | -3.48 | -0.43 | -0.52 | -0.53 | -0.50 | -0.53 | -0.60 | -0.65 | -5.68 | -30.37 | -44.82 | -36.55 | - | -1.19 | -1.14 | -1.09 | -0.99 | -1.11 | -0.31 |
| R&D Expense | 3.58M | 2.82M | 4.43M | 5.47M | 6.28M | 9.32M | 9.28M | 8.13M | 9.94M | 10.99M | 14.40M | 13.62M | 8.57M | 10.75M | 10.12M | - | 13.01M | 12.61M | 11.91M | - | 11.71M | 12.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 29.77M | 36.93M | 54.39M | 62.95M |
| Operating Income | -19.55M | -39.82M | -29.77M | -36.93M | -54.39M | -62.95M |
| EBITDA | - | - | -29.38M | -34.75M | -51.71M | -58.68M |
| Interest Expense | - | - | - | 0 | 300.00K | 8.00K |
| Pretax Income | - | - | -29.51M | -35.31M | -52.67M | -59.52M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -19.46M | -39.77M | -29.51M | -35.31M | -52.67M | -59.52M |
| Diluted EPS | -9.60 | -2.19 | -2.21 | -2.65 | -15.28 | -4.40 |
| R&D Expense | 15.94M | 28.17M | 37.70M | 32.12M | 43.80M | 48.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 55.22M | 154.02M | 16.00M | 35.73M | 114.91M | 62.12M |
| Current Assets | - | - | - | 13.62M | 33.77M | 113.00M | 60.84M |
| Cash & Equivalents | - | 53.61M | 124.66M | 11.54M | 29.88M | 110.76M | 59.05M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.62M | 6.81M | 70.42M | 137.58M | 11.08M | 5.93M |
| Current Liabilities | - | 4.58M | 6.20M | 5.54M | 7.29M | 10.53M | 5.92M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 637.00K | 674.00K | 1.08M | 549.00K |
| Total Equity | -23.13M | -42.12M | 147.21M | -54.42M | -101.84M | 103.83M | 56.18M |
| Shares Outstanding | - | - | - | 13.34M | 13.34M | 13.35M | 13.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.54M | -37.98M | -26.95M | -34.55M | -51.12M | -51.83M |
| Investing Cash Flow | 7.38M | -23.38M | -1.13M | -246.00K | 15.87M | -46.00K |
| Financing Cash Flow | 47.27M | 132.41M | 26.46M | 53.12M | 116.13M | 163.00K |
| Capital Expenditure | -24.00K | -198.00K | -1.13M | -246.00K | -52.00K | -46.00K |
| Free Cash Flow | -18.56M | -38.18M | -28.09M | -34.79M | -51.17M | -51.87M |
| Net Change in Cash | - | - | -1.62M | 18.33M | 80.89M | -51.71M |
| Share Buybacks | - | - | - | 4.40M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 46.2% | -27.0% | 54.2% | 34.7% | -50.7% | -105.9% |
| ROCE % | -38.6% | -26.9% | -284.7% | -129.8% | -52.1% | -112.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 9.90% | 4.00M | $11.80M |
| 2 | BVF Inc. | 8.01% | 3.24M | $9.55M |
| 3 | Acorn Capital Advisors, LLC | 7.03% | 2.84M | $8.38M |
| 4 | StepStone Group LP | 6.59% | 2.66M | $7.85M |
| 5 | Adar1 Capital Management, LLC | 5.54% | 2.24M | $6.60M |
| 6 | Vivo Capital, LLC | 4.77% | 1.93M | $5.69M |
| 7 | Vestal Point Capital, LP | 4.52% | 1.83M | $5.39M |
| 8 | Blackrock Inc. | 3.71% | 1.50M | $4.42M |
| 9 | Trails Edge Capital Partners, LP | 3.56% | 1.44M | $4.24M |
| 10 | Vanguard Capital Management LLC | 3.56% | 1.44M | $4.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OKUR
OnKure management will hold one-on-one investor meetings in New York - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxONklzb2ppbVZBOU5hQkFhdHhFd3Q2bFJDOXBWa2tfaUJsM1BXd0xuRlNobVZ6TjkzdzZjMWROX2IxU19YS1hOaURGNzVXMkhjRkZKa2s1MDdEZU5ERFpkX3ZfT3EteE0xSlZNaW5sWmgxUVVJZHRCOVlCVEEyeEZXODQ4eGNzWGFZQW8wM0…
OKUR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE0wZkQwZi1Nd0piWm1vZ1Vwd29XTGl3Z1NTNFVJSWRxUnI3TTVpWl9zdjFobFZ0UUtXd05hcUZoUUVsZm04enc?oc=5" target="_blank">OKUR</a> <font color="#6f6f6f">Finviz</font>…
We're Not Very Worried About OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVHVvOXdsakJYVGlsU1hXM1lOTnFqeV9udFktc2FCSDZQSXF0LVJLUERIbU5zODlURkJzTV9KWm40X1dyQjQwLUlUQzNNSXVjRkVYeXlfM1ZRQnZ6bjh5a1RfVVowSDVMbHYwSHFFWjFBd2wyNlAwamZOUzQ0eG9GRkdRekQ2QUttcU9oc0…
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5IRGJRUktScHRpSTV1TmtWRkI5VVBVOU1mZEYteGkxOWtCc3hPWW5tMVBRWlVlNldLNUtCbVlEblFPaW1HOUxqbEduSlhGTHVOTjdkLVdMWkFDZ2FuMVpuUkEwaENtSXlOc25CZ2wxQ20xNV9jc2o4?oc=5" target="_blank">OnKure …
OKUR Shares Face Turbulence Amid Financial Downturn - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTFBRbUtSZlg4dmxKLVFHSGJsUWRjT2t3LWMxSF9mU3dBR0hHeHFTdmw1Wm84LV8wRHV6NTgzQ2tGWEVZb1JTb2JoeURfNXN2Sl9ULU9VejBUWHduWjE4S3NQLUptVDR6cXlwclJBQXpjSlRfeTgyTjNyTVFUZW52Y1U?oc=5" target="_bla…
OnKure to sell $150M in stock to fund drug development - Daily Camera
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQdFA5Z0JaRHZFYXRKUkdQYU94S2xoaGJNVkdXcWtTcGRjLWRJaVZkbE1OZWUwQldjUzN2SUQ2eWpXNWpVNmo0eEdNa1BrbUVBR1d5UktqdF9iRVpHUUk0MG1YVjJjSFBTSmlRQkZPMEdwTTdDRV9qY1pSWmFDT3BqRkZSUEVHY1ZSa0tSTz…
OKUR — Frequently Asked Questions
What is the current share price of OnKure Therapeutics, Inc. (OKUR)?
As of 2026-09-19 21:16 PDT, OnKure Therapeutics, Inc. (OKUR) trades at $3.40 on NasdaqGM. Its 52-week range is $2.32 to $5.27.
What is the market capitalisation of OKUR?
OnKure Therapeutics, Inc. (OKUR) has a market capitalisation of $137.34M on NasdaqGM.
What is the P/E ratio of OKUR?
OKUR trades at a trailing price-to-earnings (P/E) ratio of -1.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.69.
What is the return on equity (ROE) of OKUR?
OKUR has a return on equity (ROE) of -46.91%. Its return on capital employed (ROCE) is -112.02%.
Is OKUR a good stock to buy?
This page provides a data-driven analysis of OnKure Therapeutics, Inc. (OKUR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.